Form 8-K - Current report:
SEC Accession No. 0001193125-25-180438
Filing Date
2025-08-14
Accepted
2025-08-14 09:44:04
Documents
13
Period of Report
2025-08-14
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d795256d8k.htm   iXBRL 8-K 26102
2 EX-10.1 d795256dex101.htm EX-10.1 10316
  Complete submission text file 0001193125-25-180438.txt   154015

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA jagx-20250814.xsd EX-101.SCH 2875
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE jagx-20250814_lab.xml EX-101.LAB 17992
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE jagx-20250814_pre.xml EX-101.PRE 11277
15 EXTRACTED XBRL INSTANCE DOCUMENT d795256d8k_htm.xml XML 3636
Mailing Address 200 PINE STREET SUITE 400 SAN FRANCISCO CA 94104
Business Address 200 PINE STREET SUITE 400 SAN FRANCISCO CA 94104 415-371-8300
Jaguar Health, Inc. (Filer) CIK: 0001585608 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36714 | Film No.: 251215012
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)